Calhoun Carla, Helzlsouer Kathy J, Gallicchio Lisa
a The Prevention and Research Center, The Weinberg Center for Women's Health and Medicine, Mercy Medical Center , Baltimore , MD , USA.
J Psychosoc Oncol. 2015;33(3):263-77. doi: 10.1080/07347332.2015.1019661.
The goal of this survey-based study was to examine whether aromatase inhibitor (AI) therapy was associated with depressive symptoms and self-rated health among Black and White breast cancer survivors (N = 761). Results showed that among Black, but not White, breast cancer survivors current AI therapy was associated with a significant increase in the odds of both depressive symptoms (OR 3.59; 95% CI 1.01, 13.00) and poorer self-rated health (OR 3.16; 95% CI 1.06, 9.46). Presence of pain was significantly associated with increased odds of both outcomes among both groups. The findings underscore the importance of addressing not only physical but mental health among breast cancer survivors on AIs, especially those of Black race.
这项基于调查的研究旨在探讨芳香化酶抑制剂（AI）治疗是否与黑人和白人乳腺癌幸存者（N = 761）的抑郁症状及自评健康状况相关。结果显示，在黑人乳腺癌幸存者中，而非白人，当前的AI治疗与抑郁症状（比值比[OR] 3.59；95%置信区间[CI] 1.01，13.00）和较差的自评健康状况（OR 3.16；95% CI 1.06，9.46）的几率显著增加有关。疼痛的存在与两组中这两种结果的几率增加均显著相关。这些发现强调了在接受AI治疗的乳腺癌幸存者中，不仅要关注身体健康，还要关注心理健康的重要性，尤其是黑人种族的幸存者。
